Compare SAH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | MYGN |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 481.6M |
| IPO Year | 1997 | 1996 |
| Metric | SAH | MYGN |
|---|---|---|
| Price | $63.23 | $4.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $78.25 | $7.64 |
| AVG Volume (30 Days) | 344.1K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $9,951,630,000.00 | $771,400,000.00 |
| Revenue This Year | $4.69 | $7.19 |
| Revenue Next Year | $4.39 | $5.64 |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | 0.86 | ★ 2.33 |
| 52 Week Low | $52.00 | $3.76 |
| 52 Week High | $89.38 | $10.06 |
| Indicator | SAH | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 44.55 |
| Support Level | $62.82 | $3.93 |
| Resistance Level | $65.46 | $5.69 |
| Average True Range (ATR) | 2.31 | 0.32 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 73.38 | 27.60 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.